Abstract 443P
Background
Many patients with advanced cancer have difficulty eating and need nutritional support. This preliminary study examined the effects of individual nutritional counselling sessions on quality of life (QOL), nutritional status and eating-related distress (ERD) among patients with advanced cancer undergoing chemotherapy.
Methods
A survey was conducted in the outpatient chemotherapy center at a university hospital in Tokyo, Japan. Patients were offered individual nutritional counselling by a dietitian specializing in cancer. For the participants who completed at least two counselling sessions, we evaluated changes in their QOL (EORTC-QLQ C30), symptoms and nutritional status (PG-SGA SF) and ERD. Data were analyzed using the Wilcoxon signed rank test to compare mean differences. The ethics committee approved the study (Ethical Review No. M2015-578).
Results
Of 42 patients who applied for nutritional counselling, 8 underwent two sessions. The mean age was 70.6 ± 5.9 years and females accounted for 25.0%. Primary diseases were gastrointestinal cancer (n = 6) and lung cancer (n = 2). “Although family members and friends recommend foods to me, I am just confused” on the ERD and “fatigue” on the EORTC-QLQ C30 significantly improved (p < 0.05, respectively). There were no significant differences in the other items of the EORTC-QLQ C30 or symptoms and nutritional status on the PG-SGA SF. In total, 34 patients did not receive nutritional counselling twice because of death, changing hospitals, disease progression, or lack of coordination among researchers.
Conclusions
Our study suggests that individual nutritional counselling is slightly beneficial for patients with advanced cancer receiving chemotherapy. Further research is needed to demonstrate the effectiveness of this intervention in the future.
Clinical trial identification
UMIN registration No. UMIN000021540; was carried out prior to the start of the study.
Editorial acknowledgement
Legal entity responsible for the study
Tokyo Medical and Dental University.
Funding
Sasakawa Memorial Health Foundation.
Disclosure
S. Koshimoto: Research grant / Funding (institution): Sasakawa Memorial Health Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract